Reviva Pharmaceuticals Files 8-K on Corporate Actions

Ticker: RVPH · Form: 8-K · Filed: Dec 12, 2024

Sentiment: neutral

Topics: corporate-governance, filing-update, pharmaceuticals

TL;DR

REVIVA files 8-K: corporate changes, shareholder votes, and financials updated. Stay tuned.

AI Summary

Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on December 12, 2024, reporting on events that occurred on December 10, 2024. The filing indicates changes related to amendments to articles of incorporation or bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. The company, formerly Tenzing Acquisition Corp., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This 8-K filing signals important corporate governance updates and potential shareholder votes for Reviva Pharmaceuticals, which could impact the company's strategic direction and financial reporting.

Risk Assessment

Risk Level: medium — Filings related to corporate governance, amendments, and shareholder votes can introduce uncertainty and potential shifts in company strategy or structure.

Key Players & Entities

FAQ

What specific amendments were made to the Articles of Incorporation or Bylaws?

The filing indicates that amendments to Articles of Incorporation or Bylaws were reported, but the specific details of these amendments are not provided in the summary information.

What matters were submitted to a vote of security holders?

The 8-K filing states that matters were submitted to a vote of security holders, but the nature of these matters is not detailed in the provided text.

What financial statements and exhibits are included in this filing?

The filing lists 'Financial Statements and Exhibits' as an item, but the specific content of these statements and exhibits is not described in the summary.

When was Reviva Pharmaceuticals Holdings, Inc. formerly known as Tenzing Acquisition Corp.?

The company changed its name from Tenzing Acquisition Corp. on June 6, 2018.

What is the primary business of Reviva Pharmaceuticals Holdings, Inc. according to its SIC code?

Reviva Pharmaceuticals Holdings, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,239 words · 5 min read · ~4 pages · Grade level 14 · Accepted 2024-12-12 16:36:50

Key Financial Figures

Filing Documents

03. Amendments to Articles of Incorporation or Bylaws; Changes in Fiscal Year

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Changes in Fiscal Year. As described under Proposal 5 of Item 5.07 of this Current Report on Form 8-K, on December 10, 2024, Reviva Pharmaceuticals Holdings, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") at which, among other matters of business acted upon, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") to increase the Company's authorized shares of common stock, par value $0.0001 per share (the "Common Stock"), from 115,000,000 to 315,000,000 (the "Certificate of Amendment"). On December 10, 2024, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware and such amendment became effective immediately. The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On December 10, 2024, the Company held the Annual Meeting. The stockholders of the Company acted upon the following proposals at the Annual Meeting: (1) the election of directors, (2) the ratification of the appointment of Moss Adams LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024, (3) the approval, on an advisory basis, of the executive compensation of the Company's named executive officers, (4) the vote, on an advisory basis, on how often the Company will conduct an advisory vote on executive compensation, and (5) the approval of the Certificate of Amendment to increase the Company's authorized shares of Common Stock from 115,000,000 to 315,000,000 ("Proposal 5"). As there were sufficient votes at the time of the Annual Meeting to approve Proposal 5, Proposal 6 (as defined below) was unnecessary and such adjournment proposal was not submitted to the stockholders for approval at the Annual Meeting, as further described below. The final voting results were as follows: 1. The election of each of Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel and Les Funtleyder as directors to hold office for a term of one year, until their successor is duly elected and qualified or they are otherwise unable to complete their term. The votes were cast for this matter as follows: Votes Broker Non- Nominees Votes For Withheld Votes Laxminarayan Bhat 6,877,403 4,896,145 10,762,193 Parag Saxena 6,861,061 4,912,487 10,762,193 Richard Margolin 6,938,763 4,834,785 10,762,193 Purav Patel 6,661,134 5,112,414 10,762,193 Les Funtleyder 6,949,314 4,824,234 10,762,193 2. The proposal to ratify the appointment of Moss Adams LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024, was approved based upon the following votes: Votes For Votes Aga

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 3.1 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Reviva Pharmaceuticals Holdings, Inc., dated December 10, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVIVA PHARMACEUTICALS HOLDINGS, INC. Date: December 12, 2024 By: /s/ Narayan Prabhu Narayan Prabhu Chief Financial Officer

View on Read The Filing